DK2945642T3 - Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme - Google Patents

Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme Download PDF

Info

Publication number
DK2945642T3
DK2945642T3 DK14700872.6T DK14700872T DK2945642T3 DK 2945642 T3 DK2945642 T3 DK 2945642T3 DK 14700872 T DK14700872 T DK 14700872T DK 2945642 T3 DK2945642 T3 DK 2945642T3
Authority
DK
Denmark
Prior art keywords
protein
disease
prevention
factor
treatment
Prior art date
Application number
DK14700872.6T
Other languages
English (en)
Inventor
Kai Christoph Wollert
Mortimer Korf-Klingebiel
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Application granted granted Critical
Publication of DK2945642T3 publication Critical patent/DK2945642T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
DK14700872.6T 2013-01-17 2014-01-16 Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme DK2945642T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151593 2013-01-17
PCT/EP2014/050788 WO2014111458A2 (en) 2013-01-17 2014-01-16 Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases

Publications (1)

Publication Number Publication Date
DK2945642T3 true DK2945642T3 (da) 2024-05-27

Family

ID=47559322

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14700872.6T DK2945642T3 (da) 2013-01-17 2014-01-16 Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme

Country Status (16)

Country Link
US (1) US10369198B2 (da)
EP (2) EP2945642B1 (da)
JP (4) JP6809789B2 (da)
CN (6) CN104968361B (da)
CA (1) CA2898128A1 (da)
DK (1) DK2945642T3 (da)
ES (1) ES2986021T3 (da)
FI (1) FI2945642T3 (da)
HR (1) HRP20240623T1 (da)
HU (1) HUE068364T2 (da)
LT (1) LT2945642T (da)
PL (1) PL2945642T3 (da)
PT (1) PT2945642T (da)
RS (1) RS65553B1 (da)
SI (1) SI2945642T1 (da)
WO (1) WO2014111458A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6809789B2 (ja) * 2013-01-17 2021-01-06 メディツィーニシェ・ホーホシューレ・ハノーファーＭｅｄｉｚｉｎｉｓｃｈｅ Ｈｏｃｈｓｃｈｕｌｅ Ｈａｎｎｏｖｅｒ 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
EP4417255A3 (en) 2013-11-21 2024-10-23 The Brigham and Women's Hospital Inc. Compositions and methods for treating pulmonary hypertension
JP6955443B2 (ja) * 2014-08-01 2021-10-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 肺動脈性肺高血圧症の処置に関する方法および組成物
US10435757B1 (en) 2016-06-15 2019-10-08 University Of South Florida Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof
CN108802372B (zh) * 2018-06-19 2021-05-11 上海伦泽生物科技有限公司 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒
EP4087489B1 (en) 2020-01-08 2025-05-14 Vitruvia Holdings Inc. Methods and computing system for processing ultrasound image to determine health of subdermal tissue
WO2021148411A1 (en) 2020-01-21 2021-07-29 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure
CN114149498B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体在防治2型糖尿病中的应用
CN114149500B (zh) * 2020-09-07 2023-12-01 复旦大学附属华山医院 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用
CN114149499B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用
MX2023007474A (es) 2020-12-23 2023-09-13 Boehringer Ingelheim Int Proteinas de la capside viral con especificidad para las celulas del tejido cardiaco.
MX2024000175A (es) * 2021-07-08 2024-03-05 Tenaya Therapeutics Inc Casetes de expresión optimizada para genoterapia.
CN119343365A (zh) 2022-06-03 2025-01-21 勃林格殷格翰国际有限公司 骨髓源性生长因子的重组表达
KR20250059408A (ko) 2022-09-08 2025-05-02 베링거 인겔하임 인터내셔날 게엠베하 심장성 쇼크를 치료하는 데 사용하기 위한 골수-유래 성장 인자
WO2025047991A1 (en) 2023-09-01 2025-03-06 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing a liver disorder
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
TW202539726A (zh) 2023-12-06 2025-10-16 德商百靈佳殷格翰國際股份有限公司 包含骨髓衍生性生長因子之新穎調配物
CN120738287B (zh) * 2025-07-03 2026-02-24 广州医科大学附属妇女儿童医疗中心 急性低灌注动物模型的构建方法及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
AU717542B2 (en) 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
CA2265923A1 (en) 1996-09-13 1998-03-19 Sagami Chemical Research Center Human proteins having secretory signal sequences and dnas encoding these proteins
JP2001506484A (ja) * 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
CA2278621A1 (en) * 1997-01-29 1998-07-30 Cornell Research Foundation, Inc. Multiple site delivery of adenoviral vector for the induction of angiogenesis
ATE488584T1 (de) 1999-05-26 2010-12-15 Next Biomed Technologies Nbt Oy Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften
DK1212417T3 (da) * 1999-06-02 2008-09-01 Genentech Inc Fremmelse eller inhibering af angiogenese og vaskularisering
WO2001012669A1 (en) 1999-08-16 2001-02-22 Universita' Degli Studi Di Siena Vegf-d and angiogenic use thereof
JP2004516013A (ja) * 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
WO2002081681A1 (fr) * 2001-03-30 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Nouvelle utilisation de la cytokine sf20
DE10119804A1 (de) * 2001-04-23 2002-10-24 Brahms Ag Entzündungsspezifische Peptide und deren Verwendungen
US7452968B2 (en) * 2003-01-02 2008-11-18 University Of Southern California Secreted protein factor and cell membrane-bound splice variant
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US8486438B2 (en) 2004-01-29 2013-07-16 Brown University Methods for progenitor cell recruitment and isolation
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US20080004232A1 (en) * 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2130547A1 (en) * 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
US8623358B2 (en) * 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
WO2011094446A1 (en) 2010-01-27 2011-08-04 Neumedicines, Inc A method for treating brain cancer using a novel tumor suppressor gene and secreted factor
KR20120095063A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
JP6809789B2 (ja) * 2013-01-17 2021-01-06 メディツィーニシェ・ホーホシューレ・ハノーファーＭｅｄｉｚｉｎｉｓｃｈｅ Ｈｏｃｈｓｃｈｕｌｅ Ｈａｎｎｏｖｅｒ 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤

Also Published As

Publication number Publication date
CN110922468B (zh) 2024-09-24
ES2986021T3 (es) 2024-11-08
JP2016506911A (ja) 2016-03-07
CN104968361B (zh) 2019-12-17
EP2945642B1 (en) 2024-02-21
PL2945642T3 (pl) 2024-07-29
CN110903378A (zh) 2020-03-24
JP2023025005A (ja) 2023-02-21
US10369198B2 (en) 2019-08-06
CN110922467A (zh) 2020-03-27
JP7685737B2 (ja) 2025-05-30
EP2945642A2 (en) 2015-11-25
SI2945642T1 (sl) 2024-07-31
EP3747457A2 (en) 2020-12-09
CA2898128A1 (en) 2014-07-24
CN111100197B (zh) 2024-11-15
CN110922468A (zh) 2020-03-27
WO2014111458A3 (en) 2014-09-12
RS65553B1 (sr) 2024-06-28
EP3747457A3 (en) 2021-03-03
JP2025143268A (ja) 2025-10-01
CN111100197A (zh) 2020-05-05
HUE068364T2 (hu) 2024-12-28
FI2945642T3 (fi) 2024-05-10
CN110894226A (zh) 2020-03-20
JP2020203894A (ja) 2020-12-24
WO2014111458A2 (en) 2014-07-24
HK1215540A1 (en) 2016-09-02
LT2945642T (lt) 2024-06-25
PT2945642T (pt) 2024-05-27
JP6809789B2 (ja) 2021-01-06
HRP20240623T1 (hr) 2024-08-02
CN104968361A (zh) 2015-10-07
US20150352186A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
SI2935303T1 (sl) 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
DK3334422T3 (da) Anvendelse af cannabidiolsyre i behandling af epilepsi
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
IL240845A0 (en) Compounds and uses thereof for the modulation of hemoglobin
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
EP3960735C0 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
IL240727B (en) Peptides and compositions for treatment of joint damage
IL260684B (en) Treatment for modulating gut microbiota
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
IL252026B (en) Humanized anti-complement factor c1q antibodies and uses thereof
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis
DK4005570T3 (da) Pridopidin til anvendelse behandling af retts syndroe
EP3190886C0 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME